Fianlimab/Cemiplimab Yields Activity in Pretreated Metastatic Melanoma
The safety of fianlimab plus cemiplimab appears consistent with the safety profile previously observed with each individual agent among patients with previously treated metastatic melanoma in a phase 1 study.
Worse Treatment Outcomes Appear in BRCA+ mCRPC Vs Non-BRCA Disease
Germline and somatic BRCA1/2 alterations correlate with worse survival in patients with metastatic castration-resistant prostate cancer in the CAPTURE trial.
Tislelizumab Yields QOL Benefit Over Sorafenib in First-Line Hepatocellular Carcinoma
Patients with unresectable hepatocellular carcinoma experienced an improvement in several health-related quality of life measures following treatment with first-line tislelizumab compared with sorafenib.
Adding Palbociclib to Fulvestrant Did Not Yield Better Efficacy in ER-positive/HER2-Negative Metastatic Breast Cancer
Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer did not derive further benefit when palbociclib was added to fulvestrant.
Favorable Responses Derived From Trastuzumab Deruxtecan in HER2+ NSCLC
Trastuzumab deruxtecan demonstrates clinically meaningful benefit in patients with non¬–small cell lung cancer harboring HER2 mutations, according to results from the DESTINY-Lung02 trial.
Extended Follow-up Supports Use of Larotrectinib in NTRK Fusion+ Lung Cancer
Follow-up to the phase 2 NAVIGATE and phase 1 LOXO-TRK-14001 trials showed durable responses and extended survival in patients with NTRK fusion–positive lung cancer who were treated with larotrectinib.
Similar Efficacy Seen With More Intense Chemotherapy Plus Panitumumab in mCRC
Adding irinotecan to chemotherapy plus panitumumab for treatment of metastatic colorectal cancer did not result in a significant impact on efficacy.
Prolonged Survival Observed With Nivolumab Plus Ipilimumab in Metastatic NSCLC
The 5-year analysis of the phase 3 CheckMate 227 trial showed consistent, long-term survival with nivolumab plus ipilimumab for metastatic non–small cell lung cancer.
Addition of Darolutamide to ADT and Docetaxel Did not Worsen Safety in mHSPC
Adverse effects were found to be similar between patients with metastatic hormone-sensitive prostate cancer who were treated with darolutamide plus androgen deprivation therapy and docetaxel vs androgen deprivation therapy and docetaxel alone.
Cutaneous cGVHD Responds to Topical Ruxolitinib
Topical ruxolitinib cream resulted in benefit to patients with cutaneous chronic graft-vs-host based on results of a trial that were presented at the 2022 Tandem Meeting.
Molecular Characteristics of Resistance to CD19-Directed CAR T Cells Revealed in Pediatric ALL
Investigators uncovered potential mechanisms of resistance to CD19-directed CAR T-cell therapy in patients with pediatric acute lymphoblastic leukemia.
CLDN6-Targeting CAR T-Cell Therapy Produces Acceptable Responses in Solid Tumors
The CAR T-cell product BNT211 when used with or without a CAR T cell–amplifying RNA vaccine produced considerable responses and safety in patients with CLDN6-positive advanced solid tumors.
No Significant PFS Improvement Noted in Advanced Squamous Cell Penile Cancer Treated With Immunotherapy
Data from a phase 2 trial of atezolizumab with or without radiotherapy showed some antitumor activity in advanced squamous cell carcinoma of the penis, despite failing to meet the primary end point of progression-free survival.
Sintilimab Improved Response Rates for Metastatic or Recurrent Pancreatic Adenocarcinoma
Although sintilimab improved overall response rates and maintained a tolerable safety profile for patients with metastatic or recurrent pancreatic adenocarcinoma, it did not improve overall or progression-free survival.
Acalabrutinib Shows Strong Survival Benefit With Favorable Risk-Benefit Profile for Relapsed/Refractory CLL
Acalabrutinib produced positive quality-adjusted survival benefits over other treatment options for patients with relapsed/refractory chronic lymphocytic leukemia.
Standard of Care More Effective in Reducing MRD Than Ibrutinib Plus Venetoclax for CLL
Standard of care treatment was superior to the combination of ibrutinib plus venetoclax in terms of decreasing minimal residual disease for previously untreated patients with chronic lymphocytic leukemia.
IDFS and DRFS Benefit Found in Adjuvant Chemotherapy for Premenopausal Women With HR+/HER2- Breast Cancer
Premenopausal women with hormone receptor-positive, HER2-negative breast cancer saw a survival benefit when treated with adjuvant chemotherapy.
2 Clarke Drive Cranbury, NJ 08512